Biopharmaceutical royalties buyer Royalty Pharma plc (Nasdaq:RPRX) announced on Thursday that it has acquired a synthetic royalty on US sales of Geron Corporation's (NASDAQ: GERN) RYTELO (imetelstat) for USD125m.
RYTELO is an FDA-approved treatment for low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anaemia. Geron is currently enrolling a Phase 3 trial of imetelstat in myelofibrosis patients who are relapsed/refractory to JAK-inhibitors.
This acquisition increases Royalty Pharma's synthetic royalty funding for 2024 to USD925m.
Royalty Pharma will receive tiered royalty payments on RYTELO's US net sales, ranging from 7.75% of annual net sales up to USD500m, and 3.0% of annual net sales between USD500m and USD1bn, to 1.0% of annual net sales over USD1bn. Payments to Royalty Pharma will cease if the aggregate royalties payable through 30 June 2031 reach a multiple of 1.65 its investment, otherwise the royalty payments will continue until Royalty Pharma receives a multiple of 2.0 its investment.
European Commission approves Sobi's Aspaveli for rare kidney diseases
US FDA accepts IND application for AskBio's AB-1009
EspeRare and n-Lorem partner to expand European access to ASO therapies for rare genetic diseases
Bionpharma and STEERLife's Etravirine tablets approved by US FDA
Kestra partners with Biobeat to add cuffless blood pressure monitoring to wearable defibrillator
argenx secures FDA priority review for VYVGART in seronegative myasthenia gravis
Abbisko Therapeutics reports US FDA acceptance of pimicotinib NDA
Formosa Pharmaceuticals licenses APP13007 ophthalmic therapy to Samil for South Korea
Summit Therapeutics submits FDA application for ivonescimab in EGFR-mutated lung cancer
Sanofi's Teizeild approved in EU to delay stage 3 type 1 diabetes
Renalytix expands US clinical footprint with three kidneyintelX.dkd integrations
EQT Life Sciences exits Vivasure Medical in EUR185m sale to Haemonetics
FDA accepts NDA resubmission for Camurus' acromegaly drug Oclaiz